INDP - Indaptus stock soars 37% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors

Indaptus Therapeutics (NASDAQ:INDP) said the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to begin a phase 1 trial of Decoy20 to treat patients with advanced solid tumors when currently approved therapies have failed. The company plans to begin the study in H2 2022. "This is an important milestone for Indaptus, which brings us one step closer to our goal of demonstrating the utility of a multi-targeted and antigen-agnostic, systemic immunotherapy that primes and activates both innate and adaptive anti-tumor immune responses," said Indaptus (INDP) CEO Jeffrey Meckler. INDP +37.20% to $3.43 premarket May 19

For further details see:

Indaptus stock soars 37% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors